Stocks›Healthcare›TARS

TARS

TARSUS PHARMACEUTICALS, INC.

NasdaqResearch view

$75.69−0.36%

Sep 25 close · 1D EOD · Databento

HealthcareBiological Products, (No Diagnostic Substances)Mid-capSEC EDGAR FY 2025-12-31

What happened

Daily closes · dots are Wire stories

What’s next

Expected around early November, going by its own filing history. The company has not announced a date yet. Its matching report came Nov 4, 2025 and Nov 13, 2024, before the open.

Last report

Aug 6, 2026+6.59%

before the open

Last 4, next close

median 5.61% either way

up 2 of 4

Every report since 2022 →

DateEventSourceNext close

Aug 6Earnings release, before the open · 8-KSEC EDGARSEC EDGAR ↗+6.59%

Next close = the first close after the event against the close before it. Prior-session closes only; not a call, not advice.

Big days · last year

Daily closes · Databento EOD

17 big days: a close more than 5.23% from the one before, three times TARS’s median day (1.74%). On 1 of 17, its largest peers moved the same way at least half as far. We show what we hold, never a cause.

Shaded: since our stories began, Jun 10, 2026

17Sep 4, 2026
Sep 4, 2026Nothing in our recordNo TARS story, brief or results filing in our record that dayGroup −1.6% did not move with it
−1.6% did not move with itMRNA −2.2 · BIIB −1.6 · AMGN −1.6 · GILD −0.1
+9.10%
16Sep 2, 2026
Sep 2, 2026Nothing in our recordNo TARS story, brief or results filing in our record that dayGroup +0.4% did not move with it
+0.4% did not move with itBIIB +3.1 · MRNA −2.2 · AMGN +1.1 · GILD −0.2
+11.76%
15Aug 6, 2026
Aug 6, 2026ResultsThe first close after a results filing (SEC 8-K, Item 2.02)Group −0.7% did not move with it
−0.7% did not move with itMRNA −4.3 · AMGN −0.7 · GILD −0.7 · BIIB −0.2
+6.59%
14Jul 20, 2026
Jul 20, 2026Nothing in our recordNo TARS story, brief or results filing in our record that dayGroup −1.9% did not move with it
−1.9% did not move with itMRNA −3.8 · BIIB −2.9 · GILD −0.8 · AMGN −0.6
−6.02%
13Jul 14, 2026
Jul 14, 2026Nothing in our recordNo TARS story, brief or results filing in our record that dayGroup −1.2% did not move with it
−1.2% did not move with itBIIB −8.2 · AMGN −1.4 · GILD −1.0 · MRNA +0.6
−5.40%
12Jul 10, 2026
Jul 10, 2026Nothing in our recordNo TARS story, brief or results filing in our record that dayGroup −1.9% did not move with it
−1.9% did not move with itMRNA −10.8 · GILD −3.7 · BIIB +0.1 · AMGN −0.1
−9.35%
11Jul 9, 2026
Jul 9, 2026Nothing in our recordNo TARS story, brief or results filing in our record that dayGroup −0.7% did not move with it
−0.7% did not move with itMRNA +3.7 · AMGN −1.2 · GILD −0.7 · BIIB −0.7
−5.30%
10Jul 2, 2026
Jul 2, 2026Nothing in our recordNo TARS story, brief or results filing in our record that dayGroup +3.9% moved the same way
+3.9% moved the same wayMRNA +10.0 · GILD +4.2 · AMGN +3.5 · BIIB +3.0
+7.47%
9May 20, 2026
May 20, 2026Before our storiesGroup +0.2% did not move with it
+0.2% did not move with itMRNA +5.3 · BIIB −1.4 · AMGN +0.3 · GILD +0.1
+5.71%
8May 13, 2026
May 13, 2026Before our storiesGroup −0.7% did not move with it
−0.7% did not move with itMRNA −5.3 · BIIB +2.6 · GILD −1.4 · AMGN +0.1
+8.07%
7Apr 16, 2026
Apr 16, 2026Before our storiesGroup −0.3% did not move with it
−0.3% did not move with itBIIB −2.5 · GILD −0.9 · MRNA +0.8 · AMGN +0.3
−5.68%
6Mar 25, 2026
Mar 25, 2026Before our storiesGroup +2.2% did not move with it
+2.2% did not move with itMRNA +4.3 · BIIB +2.9 · AMGN +1.6 · GILD +0.1
+6.03%
5Feb 24, 2026
Feb 24, 2026ResultsThe first close after a results filing (SEC 8-K, Item 2.02)Group −0.1% did not move with it
−0.1% did not move with itGILD −1.5 · AMGN +0.9 · BIIB −0.6 · MRNA +0.5
+7.79%
4Jan 28, 2026
Jan 28, 2026Before our storiesGroup −0.6% did not move with it
−0.6% did not move with itAMGN −2.6 · GILD −0.9 · BIIB +0.4 · MRNA −0.3
−5.83%
3Nov 10, 2025
Nov 10, 2025Before our storiesGroup +0.7% did not move with it
+0.7% did not move with itAMGN +1.1 · MRNA +0.9 · GILD −0.6 · BIIB +0.5
+6.65%
2Oct 15, 2025
Oct 15, 2025Before our storiesGroup +0.5% did not move with it
+0.5% did not move with itMRNA +5.6 · AMGN +1.2 · BIIB −1.1 · GILD −0.1
+7.33%
1Oct 3, 2025
Oct 3, 2025Before our storiesGroup +1.2% did not move with it
+1.2% did not move with itBIIB +3.0 · GILD +1.9 · MRNA +0.4 · AMGN +0.2
+10.89%

A story on the same day is not a cause, and a group move is not proof either. Group: AMGN, GILD, MRNA, BIIB, the largest companies in TARS’s SEC industry; “the same way” means the same direction and at least half as far. Prior-session closes only; not a call, not advice.

The numbers · FY2025, filed

SEC EDGAR

Market cap$3.3B

Revenue$451.4M+146.70%

Net income$-66.0M

EPS, diluted$-1.59+48.20%

Operating margin-15.7%

Return on equity-19.2%

Debt / equity0.21

All filed figures

Snapshot

SEC EDGAR · FY 2025-12-31

SectorHealthcare

Market Cap$3.3B

Enterprise Value$3.2B

Income$-66.0M

Sales$451.4M

Book/sh$7.83

Cash/sh$4.24

Dividend TTM$0.00

Payout—

Employees—

IPO—

Quick Ratio3.82

Current Ratio3.85

Debt/Eq0.21

EPS (ttm)$-1.59

EPS this Y48.2%

EPS past 3/5Y—

Sales past 3/5Y159.5%

EPS Y/Y TTM48.2%

Sales Y/Y TTM146.7%

Shs Outstand43.88M

ROA-11.7%

ROE-19.2%

ROIC-31.9%

Gross Margin—

Oper. Margin-15.7%

Profit Margin-14.6%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$57.0M

FY21

$25.8M

FY22

$17.4M

FY23

$183.0M

FY24

$451.4M

FY25

Operating leverage — margins

GrossOperatingNet

Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it

USD	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$57.0M	$25.8M	$17.4M	$183.0M	$451.4M
Gross Profit	—	—	—	—	—
Operating Income	$-12.2M	$-62.7M	$-143.2M	$-120.6M	$-71.0M
Net Income	$-13.8M	$-62.1M	$-136.0M	$-116.0M	$-66.0M
Diluted EPS	$-0.67	$-2.52	$-4.62	$-3.07	$-1.59
Operating Cash Flow	$3.7M	$-49.0M	$-117.5M	$-83.0M	$-12.5M
Free Cash Flow	$3.2M	$-49.5M	$-119.0M	$-84.6M	$-22.3M

Same industry

In the screener →

AMGN$224.2B GILD$187.1B MRNA$79.4B BIIB$33.6B EXEL$14.4B NBIX$14.1B HALO$12.9B TWST$11.5B

Build basket with TARS Screener

Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.